First Time Loading...

Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 740 000 KRW 0.54% Market Closed
Updated: Jun 19, 2024
Have any thoughts about
Samsung Biologics Co Ltd?
Write Note

Intrinsic Value

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. [ Read More ]

The intrinsic value of one Samsung Biologics Co Ltd stock under the Base Case scenario is 371 473.73 KRW. Compared to the current market price of 740 000 KRW, Samsung Biologics Co Ltd is Overvalued by 50%.

Key Points:
Intrinsic Value
Base Case
371 473.73 KRW
Overvaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Samsung Biologics Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Samsung Biologics Co Ltd stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Samsung Biologics Co Ltd

Current Assets 5.6T
Cash & Short-Term Investments 2T
Receivables 760.4B
Other Current Assets 2.8T
Non-Current Assets 10.9T
Long-Term Investments 42.3B
PP&E 4.8T
Intangibles 5.8T
Other Non-Current Assets 295.6B
Current Liabilities 4.6T
Accounts Payable 187.3B
Accrued Liabilities 227.3B
Short-Term Debt 572B
Other Current Liabilities 3.7T
Non-Current Liabilities 1.9T
Long-Term Debt 267.7B
Other Non-Current Liabilities 1.6T
Efficiency

Earnings Waterfall
Samsung Biologics Co Ltd

Revenue
3.9T KRW
Cost of Revenue
-2T KRW
Gross Profit
1.9T KRW
Operating Expenses
-737.1B KRW
Operating Income
1.1T KRW
Other Expenses
-247.9B KRW
Net Income
895.3B KRW

Free Cash Flow Analysis
Samsung Biologics Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Samsung Biologics Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Positive Operating Income
Positive Net Income
60/100
Profitability
Score

Samsung Biologics Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Samsung Biologics Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Low D/E
Negative Net Debt
83/100
Solvency
Score

Samsung Biologics Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Samsung Biologics Co Ltd

Wall Street analysts forecast Samsung Biologics Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 1 047 102.86 KRW with a low forecast of 787 800 KRW and a high forecast of 1 312 500 KRW.

Lowest
Price Target
787 800 KRW
6% Upside
Average
Price Target
1 047 102.86 KRW
42% Upside
Highest
Price Target
1 312 500 KRW
77% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Samsung Biologics Co Ltd

1M 1M
-6%
6M 6M
+5%
1Y 1Y
-4%
3Y 3Y
-12%
5Y 5Y
+137%
10Y 10Y
+419%
Annual Price Range
740 000
52w Low
680 000
52w High
859 000
Price Metrics
Average Annual Return 32.78%
Standard Deviation of Annual Returns 44.35%
Max Drawdown -32%
Shares Statistics
Market Capitalization 52.7T KRW
Shares Outstanding 71 174 000
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd

Country

Korea

Industry

Life Sciences Tools & Services

Market Cap

52.7T KRW

Dividend Yield

0%

Description

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company is headquartered in Incheon, Incheon. The company went IPO on 2016-11-10. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. The company also provides cell line development and process development services. The firm distributes its products in domestic and overseas markets.

Contact

INCHEON
Incheon
300, Songdo bio-daero, Yeonsu-gu
+82324553114
https://samsungbiologics.com/

IPO

2016-11-10

Employees

-

Officers

CEO, President & Chairman of Board
Mr. John Chongbo Rim
CFO, Executive VP, MD & Director
Mr. Dong-Joong Kim
Executive Director
Dr. Tae-Han Kim Ph.D.
Executive VP and Head of Bio R&D Centre & CSO
Dr. Namjin Chung Ph.D.
Vice President & Head of Legal Compliance Team
Mr. Hyung Woo Moon
Executive VP, Chief Marketing Officer & Head of Sales Support Center
Mr. James J. Choi
Show More
Vice President, CHRO & Head of HR Support Center
Mr. Yong Park
Executive VP & Head of CDO Development Center
Dr. Brian Hosung Min Ph.D.
VP & Head of Business Consulting Team
Mr. Heekyun Lim
Executive VP & Head of EPCV Center
Dr. Kun Lo Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one Samsung Biologics Co Ltd stock?

The intrinsic value of one Samsung Biologics Co Ltd stock under the Base Case scenario is 371 473.73 KRW.

Is Samsung Biologics Co Ltd stock undervalued or overvalued?

Compared to the current market price of 740 000 KRW, Samsung Biologics Co Ltd is Overvalued by 50%.